HC Wainwright & Co. Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.9%

Neg 0% Neu 91.9% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Damora Therapeutics (NASDAQ:DMRA) with a Buy and maintains $45 price target.